Founded at the Abramson Cancer Center at the University of Pennsylvania

PC3I Presents 35 Abstracts at the 2024 ASCO Annual Meeting

Graphic with text: PC3I at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

This week, oncologists from around the world are gathering to share the latest cutting-edge cancer research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. This year’s conference theme is The Art and Science of Cancer Care: From Comfort to Cure and features 17 first- and senior-authored abstracts and 18 co-authored abstracts from Innovation Faculty, Fellows, and staff at the Penn Center for Cancer Care Innovation (PC3I).

PC3I researchers’ work is rooted in delivering equitable and patient-centered care, addressing racial and ethnic barriers in oncology, and applying digital technologies to improve patient care and engagement. This year’s innovations include:

  • Leveraging behavioral economics-informed nudges to increase genetic testing in patients with newly diagnosed NSCLC;
  • Using AI to determine clinical trial eligibility and availability;
  • Implementing tailored treatment to reduce toxicity and improve survival for patients with cancer.


First- and Senior- Authored Abstracts:


Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI.
Charu Aggarwal, Daniel Sterman, Erin Alesi, Fabien Maldonado, Ranee Mehra, Christine Bestvina, Janani Reisenauer, Leigh Swartz, Sonam Puri, Omar Ibrahim, George Eapen, Caroline Duault, Mina Pichavant, Diane Del Valle, Edgar Gonzalez-Kozlova, Sacha Gnjatic, Holden Maecker, William Nichols, Francesca Barone, Paul Peter Tak
Poster Session: June 3, 1:30 ET – Abstract: 8634 | Poster: 498


Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).
Charu Aggarwal, Alex Martinez-Marti, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, Isabelle Monnet, Alfredo Sanchez, Shaker Dakhil, David Camidge, Marine Pillet, Miranda Brown, Adam Dowson, Zachary Cooper, Rakesh Kumar, Roy Herbst
Poster Session: June 3, 1:30 ET – Abstract: 8046 | Poster: 308


Start low, go slow: A systematic review and meta-analysis of upfront tailored treatment dosing in older adults with advanced cancer.
Gabriel Aleixo, William Ferrell, Julianne Ani, Tej Patel, Ravi Parikh, Ramy Sedhom
Poster Session: June 1, 9:00 ET – Abstract: 1625 | Poster: 496


A prospective study comparing AI-based clinical trial eligibility screening with traditional EMR-based screening.
Jiby Joseph-Thomas, Cristina Green, Abhishek Tibrewal, Frank Dupont, Jen Flach, Amelia Goldstein, Vivek Vaidya, Rajeev Kulkarni, Ravi Parikh
Online Publication – Abstract: e13636


Disparities in gynecologic oncology clinical trial availability in the United States: A state-level analysis.
Emily Ko, Elizabeth Tubridy, Sebastian Spataro Solorzano, Fiona Simpkins, Anna Jo Smith, Mary Boland
Online Publication – Abstract: e23128


Dynamic machine learning model to forecast patient availability for clinical trials.
Rajeev Kulkarni, Vivek Vaidya, Dhaval Parmar, Abhishek Tibrewal, Ravi Parikh
Online Publication – Abstract: e13641


Post-market study requirements and associations with timely submission and regulatory action for oncology drugs receiving accelerated approval, 2011-2023.
Martin Kurian, William Ferrell, Ernesto Perez, Rebecca Hubbard, Steven Joffe, Holly Lynch, Ronac Mamtani, Ravi Parikh
Poster Session: June 3, 9:00 ET – Abstract: 11028 | Poster: 223


Racial differences in background parenchymal enhancement, a novel marker of breast cancer.
Mattia Mahmoud, Sarah Ehsan, Elizabeth Mack, Christine Edmonds, Despina Kontos, Jinbo Chen, Oluwadamilola Fayanju, Anne Marie McCarthy
Poster Session: June 3, 1:30 ET – Abstract: 10528 | Poster: 55


iNUDGE: Integration of liquid biopsy based next generation gene sequencing in newly diagnosed NSCLC—A stepped wedge cluster randomized clinical trial.
Anthony Martella, Dylan Scholes, E. Paul Wileyto, Ann Tierney, Meagan Hume, Megan Roy, Shayma Kazmi, Christopher D’Avella, Samuel Kerr, Ramy Sedhom, Peter Gabriel, Katharine Rendle, Justin Bekelman, Abigail Doucette, Leland Boisseau, Melina Marmarelis, Charu Aggarwal
Poster Session: June 3, 1:30 ET – Abstract: TPS8664 | Poster: 520a


Barriers to enrollment in clinical trials in gynecologic oncology.
Erin McMinn, Anna Jo Smith, Dhivya Arasappan, Nathanael Koelper, Fiona Simpkins, Elizabeth Howell, Emily Ko
Online Publication – Abstract: e13511


Evaluating generalizability of landmark randomized controlled trials in common metastatic cancers using machine learning-based emulated trials.
Xavier Orcutt, Qi Long, Ronac Mamtani, Ravi Parikh
Online Publication – Abstract: e13618


BE-a-PAL: A cluster-randomized trial of algorithm-based default palliative care referral among patients with advanced cancer.
Ravi Parikh, William Ferrell, Yang Li, Jinbo Chen, Larry Bilbrey, Nicole Johnson, Jenna Steckel, Stephen Schleicher, Natalie Dickson, Justin Bekelman, Sandhya Mudumbi
Oral Abstract Session: June 2, 8:24 ET – Abstract: 12002


Human-AI teams to improve accuracy and timeliness of oncology trial prescreening: Preplanned interim analysis of a randomized trial.
Ravi Parikh, Matthew Guido, Anthony Girard, Yang Li, Likhitha Kolla, Jinbo Chen, Ezekiel Emanuel
Rapid Oral Abstract Session: June 3, 9:10 ET – Abstract: 1524


Behavioral economic interventions to embed early palliative care in community oncology (BE-EPiC): A pragmatic cluster-randomized trial.
Ramy Sedhom, William Ferrell, Jinbo Chen, Katherine Villarin, Yang Li, Kara Berwanger, Bethann Scarborough, Randall Oyer, Pallavi Kumar, Niharika Ganta, Shanthi Sivendran, Kevin Volpp, Justin Bekelman, Ravi Parikh
Poster Session: June 3, 1:30 ET – Abstract: 12075 | Poster: 204


Current diagnostic guidelines and perpetuation of inequities in ovarian cancer: A National Cancer Database study.
Anna Jo Smith, Emily Gleason, Sneha Kadiyala, Xingmei Wang, Elizabeth Howell, Anne Marie McCarthy
Poster Session: June 3, 9:00 ET – Abstract: 11027 | Poster: 222


“What you’re hearing from all of us is simplify the language”: A focus group study on biomarker testing in oncology.
Anna Jo Smith, Ian Ang, Rashmi Acharya, Tracy Moore, Sarah DeFeo, Caroline O’Brien, Emily Ko
Online Publication – Abstract: e13540


Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy.
Margaret Stalker, Suzanne Walker, Emily Lebow, Evan Anderson, Leonid Roshkovan, Sharyn Katz, Leslie Litzky, Andrew Haas, Sunil Singhal, Corey Langer, Keith Cengel, Melina Marmarelis
Online Publication – Abstract: e20093


PC3I Faculty and Fellows also served as co-authors on several abstracts:


Real-world outcomes of osimertinib (Osi) vs. afatinib or erlotinib in patients with classical vs. atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
Adam Barsouk, Omar Elghawy, Alec Heidlauf, Connie Yu, David Yang, Martin Kurian, Keshav Goel, Lynn Rushkin, Anran Huang, Teja Voruganti, Lova Sun, Aditi Singh, Roger Cohen, Charu Aggarwal, Melina Marmarelis, Corey Langer
Poster Session: June 3, 1:30 ET – Abstract: 8566 | Poster: 430


National implementation of an AI-based virtual dietitian for patients with cancer.
Marissa Buchan, Susan Bratton, Eliza Jones, Keshav Goel, Ethan Basch
Oral Abstract Session: June 4, 9:45 ET – Abstract: 1500


Racial and elderly disparities in receipt of guideline-concordant care in stage I-III breast cancer.
Brenda Castillo, Taussia Boadi, Xiaoyan Han, Lawrence Shulman, Yehoda Martei
Online Publication – Abstract: e13688


A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes.
Samuel Crawford, Charu Aggarwal, Sophia Ng, Qingqing Xu, Archana Simmons, Ashish Gulati, Mary Beth Beasley
Poster Session: June 3, 1:30 ET – Abstract: 8590 | Poster: 454


Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2.
Byoung Chul Cho, Yongsheng Wang, Enriqueta Felip, Jiuwei Cui, Alexander Spira, Joel Neal, Christina Baik, Melina Marmarelis, Eiki Ichihara, Jong-Seok Lee, Se-Hoon Lee, James Chih-Hsin Yang, Sebastian Michels, Zacharias Anastasiou, Joshua Curtin, Xuesong Lyu, Isabelle LECONTE, Leonardo Trani, Mahadi Baig, Pascale Tomasini
Rapid Oral Abstract Session: June 1, 5:00 ET – Abstract: 8516


Acute care and overall survival results of a randomized trial of a virtual health intervention during routine cancer treatment.
Robert Daly, Karolina Bryl, Raymond Baser, Angela Green, Tony Hung, Erin Gillespie, Katherine Panageas, Michael Postow, Jun Mao
Oral Abstract Session: June 4, 10:45 ET – Abstract: 1503


Immune-related adverse events after 2 years in patients with advanced non-small-cell lung cancer receiving extended immune checkpoint inhibitor therapy.
Omar Elghawy, Adam Barsouk, Jonathan Sussman, Christopher D’avella, Aditi Singh, Christine Ciunci, Kyle Robinson, John Kosteva, Corey Langer, Roger Cohen, Charu Aggarwal, Melina Marmarelis, Lova Sun
Poster Session: June 3, 1:30 ET – Abstract: 8551 | Poster: 415


Recruiting Black and White patients to a behavioral oncology clinical trial: Lessons from the DISCO trial.
Lauren Hamel, Eyouab Tadesse, Roman Grossi, Lorna Mabunda, Teneisha Austin, David Dougherty, Keri Angers, Karis Tutuska, Mai Daigle, Susan Eggly
Online Publication – Abstract: e13684


Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
Natasha Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna Minchom, Melina Marmarelis, Rachel Sanborn, James Chih-Hsin Yang, Baogang Liu, Tom John, Bartomeu Massuti, Alexander Spira, John Xie, Debropriya Ghosh, Ali Alhadab, Remy Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro
Oral Abstract Session: May 31, 2:45 ET – Abstract: LBA8505


Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry.
Christopher Manz, Eva Ruiz-Hispán, Tatiana Hernandez, Bernard Doger de Spéville Uribe, Daniel Morillo, Ignacio Mahillo, Jesus Garcia-Foncillas, William Ferrell, Ian Barnett, Emily Schriver, Ravi Parikh, Victor Moreno
Rapid Oral Abstract Session: June 3, 9:45 ET – Abstract: 12012


International medical graduates (IMG) representation at international oncology conference meetings.
Arya Mariam Roy, Ziad Bakouny, Nazli Dizman, Zeynep Irem Ozay, Bhavesh Mohan Lal, Rashad Nawfal, Marc Eid, Razane El Hajj Chehade, Marc Machaalani, Ayesha Butt, Charu Aggarwal, Tanios Bekaii-Saab, Mariana Chavez-MacGregor, Gilberto Lopes, Ariela Marshall, Martina Murphy, Taofeek Owonikoko, Alfred Lee, Toni CHOUEIRI
Clinical Science Symposium: June 1, 1:27 ET – Abstract: 9000


Training of clinical oncologists in Africa: Results of a regional survey.
Franklin Okwunze, Abdu Yesufe, Aalaa Abdou, Olasubomi Omoleye, Wah Senyuy, Surbhi Grover, Chidinma Anakwenze
Poster Session: June 3, 1:30 ET – Abstract: 9026 | Poster: 15


Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring.
Zachary Rivers, Charu Aggarwal, Marc Matrana, Josephine Feliciano, Akash Mitra, Halla Nimeiri, Rotem Ben-Shachar, Cathy Eng, Sheetal Kircher
Poster Session: June 3, 9:00 ET – Abstract: 11082 | Poster: 277


Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC.
Chiharu Sako, Chong Duan, Kevin Maresca, Sean Kent, Hugo Aerts, Ravi Parikh, George Simon, Petr Jordan
Clinical Science Symposium: June 1, 8:52 ET – Abstract: 102


Association of Fried’s frailty phenotype, but not the clinical frailty scale, with overall survival in older adults with acute myeloid leukemia.
Jeremy Schmoyer, Ashley Hadjis, Griffin White, Catherine Lai, Shannon McCurdy
Online Publication – Abstract: e23222


Off-label use of checkpoint inhibitor (CPI) monotherapy in PD-L1–negative or unknown recurrent/metastatic head and neck cancer (R/M HNSCC).
Margaret Stalker, Kewen Qu, Wei-Ting Hwang, Roger Cohen, Ronac Mamtani, Lova Sun
Poster Session: June 2, 9:00 ET – Abstract: 6025 | Poster: 328


Pre- and post-operative lung cancer recurrence prediction following curative surgery: A retrospective study using European radiomics and clinical data.
Ann Valter, Tanel Kordemets, Aydan Gasimova, Noah Waterfield Price, Lutz Freitag, Anil Vachani, David Carbone, Kersti Oselin
Poster Session: June 3, 1:30 ET – Abstract: 8066 | Poster: 328


Predictors of mood-related psychiatric disorders after cancer diagnosis.
Seiichi Villalona, Carlos Chavez Perez, E. Paul Wileyto, Samuel Takvorian, Peter Gabriel, Abigail Doucette, Daniel Blumenthal, Robert Schnoll
Online Publication – Abstract: e23043


Additionally, PC3I Faculty will serve as discussants on the following oral abstract and poster discussion sessions: 


Tailoring Treatment and Navigating Patient Preferences
Discussant: Samuel Takvorian
Oral Abstract Session: June 3, 8:36 ET

Related News